Suppressive effects of lycopene and β-carotene on the viability of the human esophageal squamous carcinoma cell line EC109

Ba Ngoc,Nguyen; Lv,Pin; Zhao,Wen‑En

doi:10.3892/ol.2018.8175

Suppressive effects of lycopene and β-carotene on the viability of the human esophageal squamous carcinoma cell line EC109

Authors:
- Nguyen Ba Ngoc
- Pin Lv
- Wen‑En Zhao
View Affiliations

Affiliations: School of Chemical Engineering and Energy, Zhengzhou University, Zhengzhou, Henan 450001, P.R. China
Published online on: March 5, 2018 https://doi.org/10.3892/ol.2018.8175
Pages: 6727-6732

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The molecular mechanisms underlying the chemopreventive effects of carotenoids in different types of cancer are receiving increasing attention. In the present study, the role of peroxisome proliferator‑activated receptor γ (PPARγ) in the effect of lycopene and β‑carotene on the viability of EC109 human esophageal squamous carcinoma cells was investigated. The viability of EC109 cells was evaluated using MTT assays. The effects of lycopene and β‑carotene on the expression of PPARγ, p21WAF1/CIP1, cyclin D1 and cyclooxygenase‑2 (COX‑2) were analyzed by western blotting. Lycopene and β‑carotene (5‑40 µM) dose‑ and time‑dependently reduced the viability of the EC109 cells. GW9662, an irreversible PPARγ antagonist, partly attenuated the decrease in EC109 cell viability induced by these carotenoids. Lycopene and β‑carotene treatments upregulated the expression of PPARγ and p21WAF1/CIP1, and downregulated the expression of cyclin D1 and COX‑2. These modulatory effects of the carotenoid treatments were suppressed by GW9662, suggesting that the inhibition of EC109 cell viability by lycopene and β‑carotene involves PPARγ signaling pathways and the modulation of p21WAF1/CIP1, cyclin D1 and COX‑2 expression.

View Figures

View References

1	Baldrick FR, Woodside JV, Elborn JS, Young IS and McKinley MC: Biomarkers of fruit and vegetable intake in human intervention studies: A systematic review. Crit Rev Food Sci Nutr. 51:795–815. 2011. View Article : Google Scholar : PubMed/NCBI
2	Boeing H, Bechthold A, Bub A, Ellinger S, Haller D, Kroke A, Leschik-Bonnet E, Müller MJ, Oberritter H, Schulze M, et al: Critical review: Vegetables and fruit in the prevention of chronic diseases. Eur J Nutr. 51:637–663. 2012. View Article : Google Scholar : PubMed/NCBI
3	Lampe JW: Health effects of vegetables and fruit: Assessing mechanisms of action in human experimental studies. Am J Clin Nutr. 70 3 Suppl:S475–S490. 1999. View Article : Google Scholar
4	Gandini S, Merzenich H, Robertson C and Boyle P: Meta-analysis of studies on breast cancer risk and diet: The role of fruit and vegetable consumption and the intake of associated micronutrients. Eur J Cancer. 36:636–646. 2000. View Article : Google Scholar : PubMed/NCBI
5	Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
6	Lin Y, Totsuka Y, Shan B, Wang C, Wei W, Qiao Y, Kikuchi S, Inoue M, Tanaka H and He Y: Esophageal cancer in high-risk areas of China: Research progress and challenges. Ann Epidemiol. 27:215–221. 2017. View Article : Google Scholar : PubMed/NCBI
7	Blot WJ, Li JY, Taylor PR, Guo W, Dawsey S, Wang GQ, Yang CS, Zheng SF, Gail M, Li GY, et al: Nutrition intervention trials in Linxian, China: Supplementation with specific vitamin/mineral combinations, cancer incidence, and disease-specific mortality in the general population. J Natl Cancer Inst. 85:1483–1492. 1993. View Article : Google Scholar : PubMed/NCBI
8	Li S, Jiang S, Jiang W, Zhou Y, Shen XY, Luo T, Kong LP and Wang HQ: Anticancer effects of crocetin in human esophageal squamous cell carcinoma KYSE-150 cells. Oncol Lett. 9:1254–1260. 2015. View Article : Google Scholar : PubMed/NCBI
9	Li JY, Taylor PR, Li B, Dawsey S, Wang GQ, Ershow AG, Guo W, Liu SF, Yang CS, Shen Q, et al: Nutrition intervention trials in Linxian, China: Multiple vitamin/mineral supplementation, cancer incidence, and disease-specific mortality among adults with esophageal dysplasia. J Natl Cancer Inst. 85:1492–1498. 1993. View Article : Google Scholar : PubMed/NCBI
10	Feige JN, Gelman L, Michalik L, Desvergne B and Wahli W: From molecular action to physiological outputs: Peroxisome proliferator-activated receptors are nuclear receptors at the crossroads of key cellular functions. Prog Lipid Res. 45:120–159. 2006. View Article : Google Scholar : PubMed/NCBI
11	Semple RK, Chatterjee VK and O'Rahilly S: PPAR gamma and human metabolic disease. J Clin Invest. 116:581–589. 2006. View Article : Google Scholar : PubMed/NCBI
12	Sporn MB, Suh N and Mangelsdorf DJ: Prospects for prevention and treatment of cancer with selective PPAR gamma modulators (SPARMs). Trends Mol Med. 7:395–400. 2001. View Article : Google Scholar : PubMed/NCBI
13	Ondrey F: Peroxisome proliferator-activated receptor gamma pathway targeting in carcinogenesis: Implications for chemoprevention. Clin Cancer Res. 15:2–8. 2009. View Article : Google Scholar : PubMed/NCBI
14	Rumi MA, Sato H, Ishihara S, Ortega C, Kadowaki Y and Kinoshita Y: Growth inhibition of esophageal squamous carcinoma cells by peroxisome proliferator-activated receptor gamma ligands. J Lab Clin Med. 140:17–26. 2002. View Article : Google Scholar : PubMed/NCBI
15	Hashimoto Y, Shimada Y, Itami A, Ito T, Kawamura J, Kawabe A, Kaganoi J, Maeda M, Watanabe G and Imamura M: Growth inhibition through activation of peroxisome proliferator-activated receptor gamma in human oesophageal squamous cell carcinoma. Eur J Cancer. 39:2239–2246. 2003. View Article : Google Scholar : PubMed/NCBI
16	Takashima T, Fujiwara Y, Hamaguchi M, Sasaki E, Tominaga K, Watanabe T, Oshitani N, Higuchi K and Arakawa T: Relationship between peroxisome proliferator-activated receptor gamma expression and differentiation of human esophageal squamous cell carcinoma. Oncol Rep. 13:601–606. 2005.PubMed/NCBI
17	Sawayama H, Ishimoto T, Watanabe M, Yoshida N, Sugihara H, Kurashige J, Hirashima K, Iwatsuki M, Baba Y, Oki E, et al: Small molecule agonists of PPAR-γ exert therapeutic effects in esophageal cancer. Cancer Res. 74:575–585. 2014. View Article : Google Scholar : PubMed/NCBI
18	Wang W, Wang R, Zhang Z, Li D and Yut Y: Enhanced PPAR gamma expression may correlate with the development of Barrett's esophagus and esophageal adenocarcinoma. Oncol Res. 19:141–147. 2011. View Article : Google Scholar : PubMed/NCBI
19	Al-Taie OH, Graf T, Illert B, Katzenberger T, Mörk H, Kraus MR, Barthelmes HU, Scheurlen M and Seufert J: Differential effects of PPAR gamma activation by the oral antidiabetic agent pioglitazone in Barrett's carcinoma in vitro and in vivo. J Gastroenterol. 44:919–929. 2009. View Article : Google Scholar : PubMed/NCBI
20	Cui Y, Lu Z, Bai L, Shi Z, Zhao WE and Zhao B: Beta-Carotene induces apoptosis and up-regulates peroxisome proliferator-activated receptor gamma expression and reactive oxygen species production in MCF-7 cancer cells. Eur J Cancer. 43:2590–2601. 2007. View Article : Google Scholar : PubMed/NCBI
21	Zhang X, Zhao WE, Hu L, Zhao L and Huang J: Carotenoids inhibit proliferation and regulate expression of peroxisome proliferators-activated receptor gamma (PPARγ) in K562 cancer cells. Arch Biochem Biophys. 512:96–106. 2011. View Article : Google Scholar : PubMed/NCBI
22	Zhao H, Gu H, Zhang H, Li JH and Zhao WE: PPARγ-dependent pathway in the growth-inhibitory effects of K562 cells by carotenoids in combination with rosiglitazone. Biochim Biophys Acta. 1840:545–555. 2014. View Article : Google Scholar : PubMed/NCBI
23	Nguyen BN and Zhao WE: Isolation of lycopene from the crude extract of red watermelon flesh by high-speed counter-current chromatograghy. J Zhengzhou Univ (Energ Sci). 37:43–46. 2016.
24	Yang CM, Lu IH, Chen HY and Hu ML: Lycopene inhibits the proliferation of androgen-dependent human prostate tumor cells through activation of PPARγ-LXRα-ABCA1 pathway. J Nutr Biochem. 23:8–17. 2012. View Article : Google Scholar : PubMed/NCBI
25	Yang CM, Lu YL, Chen HY and Hu ML: Lycopene and the LXRα agonist T0901317 synergistically inhibit the proliferation of androgen-independent prostate cancer cells via the PPARγ-LXRα-ABCA1 pathway. J Nutr Biochem. 23:1155–1162. 2012. View Article : Google Scholar : PubMed/NCBI
26	Chellappan SP, Giordano A and Fisher PB: Role of cyclin dependent kinases and their inhibitors in cellular differentiation and development. Curr Top Microbiol Immunol. 227:57–103. 1998.PubMed/NCBI
27	Gartel AL and Tyner AL: The growth-regulatory role of p21 (WAF1/CIP1). Prog Mol Subcell Biol. 20:43–71. 1998. View Article : Google Scholar : PubMed/NCBI
28	Wei J, Zhao J, Long M, Han Y, Wang X, Lin F, Ren J, He T and Zhang H: p21^WAF1/CIP1 gene transcriptional activation exerts cell growth inhibition and enhances chemosensitivity to cisplatin in lung carcinoma cell. BMC Cancer. 10:6322010. View Article : Google Scholar : PubMed/NCBI
29	Li H, Xiao W, Ma J, Zhang Y, Li R, Ye J, Wang X, Zhong X and Wang S: Dual high expression of STAT3 and cyclin D1 is associated with poor prognosis after curative resection of esophageal squamous cell carcinoma. Int J Clin Exp Pathol. 7:7989–7998. 2014.PubMed/NCBI
30	Yang GZ, Li L, Ding HY and Zhou JS: Cyclooxygenase-2 is overexpressed in Chinese esophageal squamous cell carcinoma, and correlated with NF-kappa B: An immunohistochemical study. Exp Mol Pathol. 79:214–218. 2005. View Article : Google Scholar : PubMed/NCBI
31	Zhang L, Wu YD, Li P, Tu J, Niu YL, Xu CM and Zhang ST: Effects of cyclooxygenase-2 on human esophageal squamous cell carcinoma. World J Gastroenterol. 17:4572–4580. 2011. View Article : Google Scholar : PubMed/NCBI
32	Sugimura A, Kiriyama Y, Nochi H, Tsuchiya H, Tamoto K, Sakurada Y, Ui M and Tokumitsu Y: Troglitazone suppress cell growth of myeloid leukemia cell lines by induction of p21^WAF1/CIP1 cyclin-dependent kinase inhibitor. Biochem Biophys Res Commun. 261:833–837. 1999. View Article : Google Scholar : PubMed/NCBI
33	Han S, Sidell N, Fisher PB and Roman J: Up-regulation of p21 gene expression by peroxisome proliferator-activated receptor gamma in human lung carcinoma cells. Clin Cancer Res. 10:1911–1919. 2004. View Article : Google Scholar : PubMed/NCBI
34	Smith AG, Beaumont KA, Smit DJ, Thurber AE, Cook AL, Boyle GM, Parsons PG, Sturm RA and Muscat GE: PPAR gamma agonist attenuate proliferation and modulate Wnt/beta-catenin signaling in melanoma cells. Int J Biochem Cell Biol. 41:844–852. 2009. View Article : Google Scholar : PubMed/NCBI